Here's how NATURE.COM makes money* and how much!

*Please read our disclaimer before using our estimates.
Loading...

NATURE . COM {}

  1. Analyzed Page
  2. Matching Content Categories
  3. CMS
  4. Monthly Traffic Estimate
  5. How Does Nature.com Make Money
  6. How Much Does Nature.com Make
  7. Keywords
  8. Topics
  9. Questions
  10. Schema
  11. Social Networks
  12. External Links
  13. Analytics And Tracking
  14. Libraries
  15. Hosting Providers
  16. CDN Services

We are analyzing https://www.nature.com/articles/s41569-023-00957-0.

Title:
Programmed death of macrophages in atherosclerosis: mechanisms and therapeutic targets | Nature Reviews Cardiology
Description:
Atherosclerosis is a progressive inflammatory disorder of the arterial vessel wall characterized by substantial infiltration of macrophages, which exert both favourable and detrimental functions. Early in atherogenesis, macrophages can clear cytotoxic lipoproteins and dead cells, preventing cytotoxicity. Efferocytosis β€” the efficient clearance of dead cells by macrophages β€” is crucial for preventing secondary necrosis and stimulating the release of anti-inflammatory cytokines. In addition, macrophages can promote tissue repair and proliferation of vascular smooth muscle cells, thereby increasing plaque stability. However, advanced atherosclerotic plaques contain large numbers of pro-inflammatory macrophages that secrete matrix-degrading enzymes, induce death in surrounding cells and contribute to plaque destabilization and rupture. Importantly, macrophages in the plaque can undergo apoptosis and several forms of regulated necrosis, including necroptosis, pyroptosis and ferroptosis. Regulated necrosis has an important role in the formation and expansion of the necrotic core during plaque progression, and several triggers for necrosis are present within atherosclerotic plaques. This Review focuses on the various forms of programmed macrophage death in atherosclerosis and the pharmacological interventions that target them as a potential means of stabilizing vulnerable plaques and improving the efficacy of currently available anti-atherosclerotic therapies. Macrophages in atherosclerotic plaques can undergo apoptosis and several forms of regulated necrosis, including necroptosis, pyroptosis and ferroptosis. In this Review, De Meyer and colleagues describe the various forms of programmed macrophage death in atherosclerosis and the potential therapeutic implications.
Website Age:
30 years and 10 months (reg. 1994-08-11).

Matching Content Categories {πŸ“š}

  • Education
  • Telecommunications
  • Business & Finance

Content Management System {πŸ“}

What CMS is nature.com built with?

Custom-built

No common CMS systems were detected on Nature.com, and no known web development framework was identified.

Traffic Estimate {πŸ“ˆ}

What is the average monthly size of nature.com audience?

πŸŒ† Monumental Traffic: 20M - 50M visitors per month


Based on our best estimate, this website will receive around 42,798,980 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Nature.com Make Money? {πŸ’Έ}


Display Ads {🎯}


The website utilizes display ads within its content to generate revenue. Check the next section for further revenue estimates.

Ads are managed by yourbow.com. Particular relationships are as follows:

Direct Advertisers (10)
google.com, pmc.com, doceree.com, yourbow.com, audienciad.com, onlinemediasolutions.com, advibe.media, aps.amazon.com, getmediamx.com, onomagic.com

Reseller Advertisers (38)
conversantmedia.com, rubiconproject.com, pubmatic.com, appnexus.com, openx.com, smartadserver.com, lijit.com, sharethrough.com, video.unrulymedia.com, google.com, yahoo.com, triplelift.com, onetag.com, sonobi.com, contextweb.com, 33across.com, indexexchange.com, media.net, themediagrid.com, adform.com, richaudience.com, sovrn.com, improvedigital.com, freewheel.tv, smaato.com, yieldmo.com, amxrtb.com, adyoulike.com, adpone.com, criteo.com, smilewanted.com, 152media.info, e-planning.net, smartyads.com, loopme.com, opera.com, mediafuse.com, betweendigital.com

How Much Does Nature.com Make? {πŸ’°}


Display Ads {🎯}

$539,300 per month
Our calculations suggest that Nature.com earns between $359,553 and $988,772 monthly online from display advertisements.

Keywords {πŸ”}

pubmed, article, google, scholar, cas, atherosclerosis, central, cell, death, biol, atherosclerotic, macrophages, macrophage, nature, mice, plaque, res, thromb, vasc, plaques, arterioscler, ferroptosis, apoptosis, nat, med, pyroptosis, meyer, necrosis, inflammasome, martinet, cells, role, activation, inflammation, human, sci, protein, nlrp, mechanisms, efferocytosis, lipid, cardiol, apolipoprotein, disease, programmed, access, mol, expression, circ, promotes,

Topics {βœ’οΈ}

nature portfolio journals nature portfolio privacy policy high-sensitivity c-reactive protein peroxisome proliferator-activated receptor-Ξ΄ advertising social media caspase-11-gasdermin d-mediated pyroptosis reprints streptozotocin-induced hyperglycemia mediated hypoxia-inducible factor-1Ξ± Ξ²-amyloid precursor protein apolipoprotein e-null mice reduce nf-ΞΊb activation nature+ nature 407 nature 536 nature 464 nature 575 nature secrete matrix-degrading enzymes pfkfb3-targeted pet tracer apolipoprotein e-deficient mice apolipoprotein e-deficient mice simvastatin-dependent plaque stabilization thp-1-derived foam cells pore-forming protein gasdermin p50/p50-mediated suppression publishing agreement annexin-derived peptide ac authors researched data targeted anti-cytokine therapies rip3-mediated macrophage necrosis placebo-controlled study author information authors drug-induced macrophage autophagy apoe3-leiden transgenic mice successful interleukin-1Ξ² inhibition dna-binding cytokine hmgb1 potential ferroptosis-related biomarkers permissions springerlink instant access placebo-controlled clinical trial regulates macrophage retention peer review personal data promotes macrophage necroptosis ripk1 kinase inhibition targeting macrophage necroptosis specific cellular target

Questions {❓}

  • Apoptosis in atherosclerosis: beneficial or detrimental?
  • Drug-induced macrophage autophagy in atherosclerosis: for better or worse?
  • Role of autophagy in atherosclerosis: foe or friend?

Schema {πŸ—ΊοΈ}

WebPage:
      mainEntity:
         headline:Programmed death of macrophages in atherosclerosis: mechanisms and therapeutic targets
         description:Atherosclerosis is a progressive inflammatory disorder of the arterial vessel wall characterized by substantial infiltration of macrophages, which exert both favourable and detrimental functions. Early in atherogenesis, macrophages can clear cytotoxic lipoproteins and dead cells, preventing cytotoxicity. Efferocytosis Ҁ” the efficient clearance of dead cells by macrophages Ҁ” is crucial for preventing secondary necrosis and stimulating the release of anti-inflammatory cytokines. In addition, macrophages can promote tissue repair and proliferation of vascular smooth muscle cells, thereby increasing plaque stability. However, advanced atherosclerotic plaques contain large numbers of pro-inflammatory macrophages that secrete matrix-degrading enzymes, induce death in surrounding cells and contribute to plaque destabilization and rupture. Importantly, macrophages in the plaque can undergo apoptosis and several forms of regulated necrosis, including necroptosis, pyroptosis and ferroptosis. Regulated necrosis has an important role in the formation and expansion of the necrotic core during plaque progression, and several triggers for necrosis are present within atherosclerotic plaques. This Review focuses on the various forms of programmed macrophage death in atherosclerosis and the pharmacological interventions that target them as a potential means of stabilizing vulnerable plaques and improving the efficacy of currently available anti-atherosclerotic therapies. Macrophages in atherosclerotic plaques can undergo apoptosis and several forms of regulated necrosis, including necroptosis, pyroptosis and ferroptosis. In this Review, De Meyer and colleagues describe the various forms of programmed macrophage death in atherosclerosis and the potential therapeutic implications.
         datePublished:2024-01-02T00:00:00Z
         dateModified:2024-01-02T00:00:00Z
         pageStart:312
         pageEnd:325
         sameAs:https://doi.org/10.1038/s41569-023-00957-0
         keywords:
            Atherosclerosis
            Cardiovascular biology
            Medicine/Public Health
            general
            Cardiology
            Cardiac Imaging
            Cardiac Surgery
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41569-023-00957-0/MediaObjects/41569_2023_957_Fig1_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41569-023-00957-0/MediaObjects/41569_2023_957_Fig2_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41569-023-00957-0/MediaObjects/41569_2023_957_Fig3_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41569-023-00957-0/MediaObjects/41569_2023_957_Fig4_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41569-023-00957-0/MediaObjects/41569_2023_957_Fig5_HTML.png
         isPartOf:
            name:Nature Reviews Cardiology
            issn:
               1759-5010
               1759-5002
            volumeNumber:21
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Nature Publishing Group UK
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Guido R. Y. De Meyer
               url:http://orcid.org/0000-0003-3848-8702
               affiliation:
                     name:University of Antwerp
                     address:
                        name:Laboratory of Physiopharmacology, University of Antwerp, Antwerp, Belgium
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Michelle Zurek
               url:http://orcid.org/0000-0003-0564-1168
               affiliation:
                     name:University of Antwerp
                     address:
                        name:Laboratory of Physiopharmacology, University of Antwerp, Antwerp, Belgium
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Pauline Puylaert
               url:http://orcid.org/0000-0002-0316-2916
               affiliation:
                     name:University of Antwerp
                     address:
                        name:Laboratory of Physiopharmacology, University of Antwerp, Antwerp, Belgium
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Wim Martinet
               url:http://orcid.org/0000-0003-1967-9343
               affiliation:
                     name:University of Antwerp
                     address:
                        name:Laboratory of Physiopharmacology, University of Antwerp, Antwerp, Belgium
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Programmed death of macrophages in atherosclerosis: mechanisms and therapeutic targets
      description:Atherosclerosis is a progressive inflammatory disorder of the arterial vessel wall characterized by substantial infiltration of macrophages, which exert both favourable and detrimental functions. Early in atherogenesis, macrophages can clear cytotoxic lipoproteins and dead cells, preventing cytotoxicity. Efferocytosis Ҁ” the efficient clearance of dead cells by macrophages Ҁ” is crucial for preventing secondary necrosis and stimulating the release of anti-inflammatory cytokines. In addition, macrophages can promote tissue repair and proliferation of vascular smooth muscle cells, thereby increasing plaque stability. However, advanced atherosclerotic plaques contain large numbers of pro-inflammatory macrophages that secrete matrix-degrading enzymes, induce death in surrounding cells and contribute to plaque destabilization and rupture. Importantly, macrophages in the plaque can undergo apoptosis and several forms of regulated necrosis, including necroptosis, pyroptosis and ferroptosis. Regulated necrosis has an important role in the formation and expansion of the necrotic core during plaque progression, and several triggers for necrosis are present within atherosclerotic plaques. This Review focuses on the various forms of programmed macrophage death in atherosclerosis and the pharmacological interventions that target them as a potential means of stabilizing vulnerable plaques and improving the efficacy of currently available anti-atherosclerotic therapies. Macrophages in atherosclerotic plaques can undergo apoptosis and several forms of regulated necrosis, including necroptosis, pyroptosis and ferroptosis. In this Review, De Meyer and colleagues describe the various forms of programmed macrophage death in atherosclerosis and the potential therapeutic implications.
      datePublished:2024-01-02T00:00:00Z
      dateModified:2024-01-02T00:00:00Z
      pageStart:312
      pageEnd:325
      sameAs:https://doi.org/10.1038/s41569-023-00957-0
      keywords:
         Atherosclerosis
         Cardiovascular biology
         Medicine/Public Health
         general
         Cardiology
         Cardiac Imaging
         Cardiac Surgery
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41569-023-00957-0/MediaObjects/41569_2023_957_Fig1_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41569-023-00957-0/MediaObjects/41569_2023_957_Fig2_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41569-023-00957-0/MediaObjects/41569_2023_957_Fig3_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41569-023-00957-0/MediaObjects/41569_2023_957_Fig4_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41569-023-00957-0/MediaObjects/41569_2023_957_Fig5_HTML.png
      isPartOf:
         name:Nature Reviews Cardiology
         issn:
            1759-5010
            1759-5002
         volumeNumber:21
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Nature Publishing Group UK
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Guido R. Y. De Meyer
            url:http://orcid.org/0000-0003-3848-8702
            affiliation:
                  name:University of Antwerp
                  address:
                     name:Laboratory of Physiopharmacology, University of Antwerp, Antwerp, Belgium
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Michelle Zurek
            url:http://orcid.org/0000-0003-0564-1168
            affiliation:
                  name:University of Antwerp
                  address:
                     name:Laboratory of Physiopharmacology, University of Antwerp, Antwerp, Belgium
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Pauline Puylaert
            url:http://orcid.org/0000-0002-0316-2916
            affiliation:
                  name:University of Antwerp
                  address:
                     name:Laboratory of Physiopharmacology, University of Antwerp, Antwerp, Belgium
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Wim Martinet
            url:http://orcid.org/0000-0003-1967-9343
            affiliation:
                  name:University of Antwerp
                  address:
                     name:Laboratory of Physiopharmacology, University of Antwerp, Antwerp, Belgium
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Nature Reviews Cardiology
      issn:
         1759-5010
         1759-5002
      volumeNumber:21
Organization:
      name:Nature Publishing Group UK
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:University of Antwerp
      address:
         name:Laboratory of Physiopharmacology, University of Antwerp, Antwerp, Belgium
         type:PostalAddress
      name:University of Antwerp
      address:
         name:Laboratory of Physiopharmacology, University of Antwerp, Antwerp, Belgium
         type:PostalAddress
      name:University of Antwerp
      address:
         name:Laboratory of Physiopharmacology, University of Antwerp, Antwerp, Belgium
         type:PostalAddress
      name:University of Antwerp
      address:
         name:Laboratory of Physiopharmacology, University of Antwerp, Antwerp, Belgium
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Guido R. Y. De Meyer
      url:http://orcid.org/0000-0003-3848-8702
      affiliation:
            name:University of Antwerp
            address:
               name:Laboratory of Physiopharmacology, University of Antwerp, Antwerp, Belgium
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Michelle Zurek
      url:http://orcid.org/0000-0003-0564-1168
      affiliation:
            name:University of Antwerp
            address:
               name:Laboratory of Physiopharmacology, University of Antwerp, Antwerp, Belgium
               type:PostalAddress
            type:Organization
      name:Pauline Puylaert
      url:http://orcid.org/0000-0002-0316-2916
      affiliation:
            name:University of Antwerp
            address:
               name:Laboratory of Physiopharmacology, University of Antwerp, Antwerp, Belgium
               type:PostalAddress
            type:Organization
      name:Wim Martinet
      url:http://orcid.org/0000-0003-1967-9343
      affiliation:
            name:University of Antwerp
            address:
               name:Laboratory of Physiopharmacology, University of Antwerp, Antwerp, Belgium
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Laboratory of Physiopharmacology, University of Antwerp, Antwerp, Belgium
      name:Laboratory of Physiopharmacology, University of Antwerp, Antwerp, Belgium
      name:Laboratory of Physiopharmacology, University of Antwerp, Antwerp, Belgium
      name:Laboratory of Physiopharmacology, University of Antwerp, Antwerp, Belgium
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

Social Networks {πŸ‘}(2)

External Links {πŸ”—}(686)

Analytics and Tracking {πŸ“Š}

  • Google Tag Manager

Libraries {πŸ“š}

  • Prism.js
  • Zoom.js

Emails and Hosting {βœ‰οΈ}

Mail Servers:

  • mxa-002c5801.gslb.pphosted.com
  • mxb-002c5801.gslb.pphosted.com

Name Servers:

  • pdns1.ultradns.net
  • pdns2.ultradns.net
  • pdns3.ultradns.org
  • pdns4.ultradns.org
  • pdns5.ultradns.info
  • pdns6.ultradns.co.uk

CDN Services {πŸ“¦}

  • Crossref

5.53s.